Swiss Parliament says no to cannabis use in scientific studies

Image
IANS Geneva
Last Updated : Jun 13 2018 | 8:00 AM IST

The Swiss Parliament has rejected a motion to allow the use of cannabis in scientific studies investigating the drug's effects.

Opponents of the rejected motion saw it as a back-door path towards liberalization, the Xinhua quoted the Swiss media as reporting on Tuesday.

After a narrow victory at the committee stage, the motion was rejected on Monday in the House of Representatives by another slim margin: 96 votes to 93, with two abstentions, the Swiss News Agency, SDA-ATS, reported.

The conservative-right Swiss People's Party and centrist Christian Democrats voted against the idea, which they saw as an implicit route towards liberalizing cannabis consumption.

Supporters of the project, which aimed to make cannabis available for academic studies about the effects of prescribed versions of the drug, had claimed that it would allow for a better understanding of possible health and social problems.

The vote came after a November 2017 federal decision to block a University of Bern study that was requested by the city's authorities into possible effects of the regulated sale of cannabis in pharmacies.

At the time, the Federal Office of Public Health, despite not rejecting the project in principle, said the request could not be granted.

It said: "Current drugs legislation does not allow the use of cannabis for non-medical reasons ... for such a study to be permitted, the law would have to be supplemented by a special legal provision for scientific pilot projects."

The Parliament's decision thus eliminated the possibility, for now, of such a legal provision being enacted.

Growing, consuming and dealing cannabis are all forbidden in Switzerland.

--IANS

tsb

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Jun 13 2018 | 7:52 AM IST

Next Story